NASDAQ: LTRN - Lantern Pharma Inc.

Rentabilité sur six mois: +0.5714%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Lantern Pharma Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

plus de détails
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2020-06-11
ISIN US51654W1018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lanternpharma.com
Цена ао 3.65
Changement de prix par jour: -0.2833% (3.53)
Changement de prix par semaine: +36.43% (2.58)
Changement de prix par mois: -7.37% (3.8)
Changement de prix sur 3 mois: +0.8596% (3.49)
Changement de prix sur six mois: +0.5714% (3.5)
Changement de prix par an: -41.04% (5.97)
Evolution du prix sur 3 ans: -47.7% (6.73)
Evolution des prix depuis le début de l'année: +9.66% (3.21)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
Total: 3.63

Efficacité

Nom Signification Grade
ROA, % -36.57 0
ROE, % -39.02 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0132 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 557.78 10
Rentabilité EPS, % 276.99 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (54 année)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (64 année)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (70 années)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

Adresse: United States, Dallas. TX, 1920 McKinney Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.lanternpharma.com